Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Return on Capital Employed (2021 - 2025)

Goldenwell Biotech filings provide 4 years of Return on Capital Employed readings, the most recent being 28.47% for Q3 2025.

  • On a quarterly basis, Return on Capital Employed changed N/A to 28.47% in Q3 2025 year-over-year; TTM through Sep 2025 was 28.47%, a N/A change, with the full-year FY2024 number at 12.3%, changed N/A from a year prior.
  • Return on Capital Employed hit 28.47% in Q3 2025 for Goldenwell Biotech, up from 25.99% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 28.47% in Q3 2025 to a low of 60.1% in Q2 2022.
  • Median Return on Capital Employed over the past 4 years was 6.08% (2021), compared with a mean of 9.88%.
  • The widest YoY moves for Return on Capital Employed: up -2488bps in 2022, down -2488bps in 2022.
  • Goldenwell Biotech's Return on Capital Employed stood at 7.45% in 2021, then plummeted by -297bps to 29.58% in 2022, then soared by 95bps to 1.57% in 2024, then skyrocketed by 1912bps to 28.47% in 2025.
  • The last three reported values for Return on Capital Employed were 28.47% (Q3 2025), 25.99% (Q2 2025), and 1.57% (Q4 2024) per Business Quant data.